PATH vs NICE

For growth investors, UiPath Inc.

(PATH) is the stronger pick with 12. 7% revenue growth year-over-year, versus 8. 5% for NICE Ltd. (NICE). NICE Ltd. (NICE) offers the better valuation at 12. 8x trailing P/E (11. 4x forward), making it the more compelling value choice. Analysts rate NICE Ltd. (NICE) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, NICE Ltd.

(NICE) is the cheapest at 12. 8x versus UiPath Inc. at 20. 6x. On forward P/E, NICE Ltd. is actually cheaper at 11. 4x.

Over the past 5 years, NICE Ltd.

(NICE) delivered a total return of -47. 0%, compared to -84. 9% for UiPath Inc. (PATH). Over 10 years, the gap is even starker: NICE returned +96. 6% versus PATH's -84. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), NICE Ltd.

(NICE) is the lower-risk stock at 0. 72β versus UiPath Inc. 's 1. 34β — meaning PATH is approximately 85% more volatile than NICE relative to the S&P 500. On balance sheet safety, UiPath Inc. (PATH) carries a lower debt/equity ratio of 3% versus 4% for NICE Ltd. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), UiPath Inc.

(PATH) is pulling ahead at 12. 7% versus 8. 5% for NICE Ltd. (NICE). On earnings-per-share growth, the picture is similar: UiPath Inc. grew EPS 500. 0% year-over-year, compared to 44. 2% for NICE Ltd.. Over a 3-year CAGR, PATH leads at 15. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

NICE Ltd.

(NICE) is the more profitable company, earning 20. 8% net margin versus 17. 5% for UiPath Inc. — meaning it keeps 20. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NICE leads at 22. 2% versus 3. 8% for PATH. At the gross margin level — before operating expenses — PATH leads at 83. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, NICE Ltd.

(NICE) trades at 11. 4x forward P/E versus 15. 9x for UiPath Inc. — 4. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PATH: 47. 9% to $15. 82.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, NICE Ltd.

(NICE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 72)). Both have compounded well over 10 years (NICE: +96. 6%, PATH: -84. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Technology sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PATH is a small-cap quality compounder stock; NICE is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.